Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)

Inclusion Criteria: * Male or female, at least 12 years of age * Female subjects of childbearing potential must have a negative urine pregnancy test at Baseline * Fitzpatrick skin type IV to VI * Acne IGA (Investigator Global Assessment) score of 2 or 3 * Inflammatory lesions of 15-60 (with no more than 2 nodules) * Non-inflammatory lesions of 20-100 * Post Inflammatory Hyperpigmentation Investigator Global Assessment (PIH IGA) score of 3,4 or 5 * Able to understand the requirements of the study and sign Informed Consent/HIPAA forms. Subjects under the legal age of consent must have the written informed consent of a parent or legal guardian Exclusion Criteria: * Female subjects who are pregnant, breast-feeding or who are of childbearing potential and not practicing a reliable method of birth control * Allergy or sensitivity to any component of the test medication * Subjects who have not complied with the wash out periods for prohibited medications * Medical condition that contraindicates participation * Skin disease/disorder that might interfere with the diagnosis of acne vulgaris or PIH * Evidence of recent alcohol or drug abuse * History of poor cooperation, non-compliance or unreliability * Exposure to an investigational drug study within 30 day of Baseline visit